The molecular pharmacology of SERMs

Trends in Endocrinology and Metabolism

Volumn 10, Issue 8, 1999, Pages 301-311

  McDonnell, Donald P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000661662     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(99)00177-0     Document Type: Review

References (22)

1. Clark, J.H. and Markaverich, B.M. (1988) Actions of ovarian steroid hormones. In The Physiology of Reproduction (Knobil, E. and Neill, J., eds), pp 675-724, Raven Press
2. Felson, D.T. et al. (1993) The effect of postmenopausal estrogen therapy on bone density in elderly women. New Engl. J. Med. 329, 1141-1146
3. Turner, R.T., Riggs, B.L. and Spelsberg, T.C. (1994) Skeletal effects of estrogen. Endocr. Rev. 15, 275-300
4. Iafrati, M.D. et al. (1997) Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice. Nat. Med. 3, 545-548
5. Zumoff, B. (1993) Hormone replacement and cardiovascular risk factors. New Engl. J. Med. 329, 1041-1043
6. Grady, D., Rubin, S.M. and Petitti, D.B. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Int. Med. 117, 1016-1037
7. Tang, M-X. et al. (1996) Effect on oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348, 429-432
8. Henderson, B.E., Paganini-Hill, A. and Ross, R.K. (1991) Decreased mortality in users of estrogen replacement therapy. Arch. Intern. Med. 151, 75-78
9. Soules, M.R. and Bremmer, W.J. (1982) The menopause and climacteric: endocrinological basis and associated symptomatology. J. Am. Geriatr. Soc. 30, 547-561
10. Dupont, W.D. and Page, D.L. (1991) Menopausal estrogen replacement therapy and breast cancer. Arch. Int. Med. 151, 67-72
11. Willis, D.B., Calle, E.E., Miracle-McMahill, H.L. and Heath, C.W. (1996) Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7, 449-457
12. Delmas, P.D. et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endomEtrium in postmenopausal women. New Engl. J. Med. 337, 1641-1647
13. O'Malley, B.W. and Schrader, W.T. (1976) The receptors of steroid hormones. Sci. Am. 234, 32-43
14. Love, R.R. et al. (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New Engl. J. Med. 326, 852-856
15. Jordan, V.C. (1992) The strategic use of antiestrogen to control the development and growth of breast cancer. Cancer 70, 977-982
16. Jordan, V.C., Collins, M.M., Rowsby, L. and Prestwich, G. (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogen activity. J. Endocrinol. 75, 305-316
17. Osborne, C.K., Hobbs, K. and Clark, G.M. (1985) Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 45, 584-590
18. Gottardis, M.M., Jiang, S-Y., Jeng, M-H. and Jordan, V.C. (1989) Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 49, 4090-4093
19. Jordan, V.C., Phelps, E. and Lindgren, J.U. (1987) Effects of anti-estrogens in castrated and intact female rats. Breast Cancer Res. Treat. 10, 31-35
20. Jordan, V.C., ed. (1996) Tamoxifen: a Guide for Clinicians and Patients, Huntington
21. Ismail, S.M. (1994) Effects of tamoxifen on uterus. Lancet 344, 622-624
22. Ugwumadu, A.H.N., Bower, D. and Ho, P.K-H. (1993) Tamoxifen induced adenomyosis and adenomyomatous endometrial polyp. Br. J. Obstet. Gynaecol. 100, 386-392